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Abstract
The transcription factor Yin Yang (YY) 1 is one of the most evolutionarily well-conserved DNA
binding proteins that is ubiquitously expressed among different tissue types. YY1 functions as a
critical regulator for a diverse set of genes, making its role in the cancerous environment elusive.
Recent studies have demonstrated that clusters of YY1 binding sites are overrepresented in
imprinted gene loci. These clustered binding sites may function as a molecular rheostat with
respect to YY1 protein levels. YY1 levels were documented to be altered in various tumor tissues
in conjunction with the transcriptional levels of the imprinted genes it regulates. This review
highlights the unexplored mechanism through which fluctuations in YY1 protein levels alter the
transcriptional status of imprinted genes containing clustered YY1 binding sites, which potentially
could affect cancer development and/or progression.
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I. INTRODUCTION
Yin Yang (YY) 1 is a transcription factor that is present in multiple species, ranging from
flying insects to placental mammals. It was identified almost 20 years ago by 3 independent
groups and was originally named YY1, DELTA1, or nuclear factor-E1.1–3 According to
numerous studies conducted during the past 2 decades, YY1 can function as an activator,
repressor, or initiator of gene transcription,4–8 and bioinformatic estimates suggest that YY1
might regulate approximately 10% of the total human gene set.9 It is interesting to note that
many of the genes bound by YY1 are involved in cell cycle regulation, including p21, p57,
cdc46, cyclin B1, and cyclin B2.10 YY1 also interacts with numerous proteins to perform
diverse cellular functions. In particular, YY1 is known to interact with several histone-
modifying complexes, including histone deacetylase 1/2, p300, and proteinarginine N-
methyltransferase 1, which may provide a molecular basis for its activator or repressor
role.5,7 Consistent with these observations, a number of studies have reported that YY1
often is overexpressed in various types of cancers.11 In addition, YY1 has been shown to
control a large fraction of imprinted genes in mammals.12,13 The exact dosage (i.e.,
expression levels) of imprinted genes is critical for organism survival, thus misregulation of
these imprinted genes often is observed in various disease states of mammals, including
imprinting-related genetic disorders and cancers.14,15 In this short review, we will discuss a
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possible route through which YY1 can cause cancers or disease states via control of
imprinted gene transcription. We will discuss (1) how YY1 and vertebrate genomes have
evolved, (2) how YY1 is involved in the regulation of several imprinted genes, and, finally,
(3) describe several known cancer-related cases where imprinted genes are misregulated,
possibly through changes in YY1 regulation.
II. EVOLUTION OF YIN YANG 1 AND VERTEBRATE GENOMES
YY1 is one of the few DNA binding proteins that has remained well-conserved during
animal evolution.16 Mammalian YY1 proteins consist of 414 amino acids and are divided
into several protein domains based on the presence of known protein motifs and unusual
amino acid compositions.4,5 Among these domains, 2 are particularly well-conserved
throughout all species of animals: a 25 amino acid recruiting Polycomb complex domain and
a 120 amino acid Gli-Kruppel zinc-finger domain (Fig. 1A).17 The recruiting Poly-comb
complex domain interacts with YY1 associated factor 2, which is responsible for joining
YY1 to RING1B, a component of Polycomb repression complex 1.18 This domain also has
been demonstrated to be crucial for YY1’s repressive functionality.17,18 The zinc-finger
domains of YY1 are responsible for binding to DNA. This DNA binding domain displays
very unusual levels of sequence conservation during evolution, producing an almost 100%
amino acid sequence identity between insects and vertebrates (Fig. 1B).16 This conservation
implies that the YY1 proteins from different species all bind to similar DNA sequences, a
fact confirmed independently by several groups.19–21 Overall, YY1 has been well-preserved
throughout different vertebrate species and flying insects, which represents a very unique
case of gene evolution in the higher eukaryotes’ genomes.
Despite the evolutionary conservation of YY1 at the protein structure level, the function of
YY1 is predicted to have diversified tremendously during animal evolution based on
multiple observations. First, the temporal expression pattern of YY1 shows a dramatic
difference between insects and vertebrates. In flying insects, Pho, the homolog of YY1, is
expressed only during early embryogenesis, which is a typical pattern for developmental
regulators.22 In contrast, the expression patterns of vertebrate YY1 are both temporally and
spatially ubiquitous.23 This observed expression pattern shift suggests that the stage-specific
developmental regulator role of Pho (YY1) in flying insects may have adapted into a more
general transcription factor role in vertebrates. Second, the size of vertebrate genomes has
increased significantly relative to that of insects. The main cause for this increase is believed
to be the accumulation of a large number of repetitive DNA elements. Many of these
repetitive elements have YY1 binding sites within their DNA sequences, thus adding a large
number of potential YY1 binding sites into the vertebrate genome.24,25 Although the exact
function of YY1 at these repetitive elements currently is unknown, it is likely that YY1
functions by silencing any “transcriptional noise” from these elements through a
surveillance-type mechanism.4 In addition to this large number of newly added YY1 binding
sites in the vertebrate genome, the number of actual genes bound by YY1 has increased
dramatically when compared with the number of Pho’s bound genes in the flying insects’
genome. This increase in the number of YY1 target genes in vertebrate genomes also is
consistent with the changes in both its expression pattern and functional shift to a general—
versus development-specific—transcription factor.
According to genome-wide surveys, YY1 has maintained a predominantly single-copy gene
status during animal evolution.16 This result is in stark contrast to the evolution pattern of
other DNA binding proteins with similar evolutionary ages, such as SP1 and E2Fs. For most
evolutionarily ancient genes, the number of gene copies has increased when the genome size
and complexity has become larger.26,27 This increased number of gene copies for DNA
binding proteins probably was necessary to help the vertebrate genome cope with new and
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diverse functional demands. YY1’s only 2 duplicated copies, REX1 and YY2, are recent
evolutionary events that occurred only in placental mammals.16 Thus, the evolutionary
significance of these duplications cannot be correlated to an increase in genome size or
complexity and have remained relatively unstudied. Overall, the evolutionary constraint on
YY1 genomic copies suggests it has developed fundamental cellular functions; thus the
protein levels of YY1 likely are monitored and controlled tightly to maintain essential gene
regulatory and signaling pathways. Consistent with this prediction, recent studies have
revealed that the genomic locus of YY1 in all vertebrates contains a unique cluster of its
own binding sites within the first intron (Fig. 2A).28 Interestingly, this cluster of YY1
binding sites was shown to regulate the transcription rate of the YY1 locus as a molecular
rheostat (Fig. 2B). The clustered YY1 binding sites promote gene activation when there are
lower-than-normal levels of YY1 protein available. However, when cellular levels of YY1
protein are higher than normal, these multiple binding sites stimulate gene repression. Thus,
this cluster of YY1 binding sites is thought to be important for the homeostasis of the YY1
protein. This observation further supports the theory that YY1 protein levels are critical for
basic cellular survival, thus requiring tight control within a very narrow range of tolerable
fluctuations.
III. YIN YANG 1 AND GENOMIC IMPRINTING
A small subset of mammalian genes are expressed mainly from one allele because of
repression of the other allele through epigenetic modification, such as DNA methylation
and/or histone modification. These “imprinted” genes occupy specific chromosomal regions,
creating larger imprinted domains ranging from 500 kilobases to 2 megabases.29 The
imprinting (allele-specific expression) and transcription for a given domain typically are
controlled by smaller genomic regions, 2 to 4 kilobases long, termed imprinting control
regions (ICRs).29 Several ICRs were confirmed to contain clusters of YY1 binding sites,
similar to those in the YY1 locus depicted in Fig. 2. The list of these loci includes the ICRs
of the paternally expressed gene (PEG) 3, guanine nucleotide binding protein, alpha-
stimulating (GNAS) complex locus, and X (inactive)-specific transcript (XIST)
domains.12,13 ICRs are known to have 2 main functions: They obtain allele-specific DNA
methylation during gametogenesis and maintain this methylation in somatic cells. ICRs also
control the transcription of nearby imprinted genes through a long-distance cis regulatory
mechanism.29 Given that YY1 binding sites are located within ICRs, the 2 main functions of
ICRs likely are mediated through YY1. Results derived from previous in vivo and in vitro
studies confirm this prediction. Reducing cellular levels of YY1 protein can alter the DNA
methylation levels at specific ICRs, such as those for PEG3 and XIST, confirming YY1’s
role in establishing and/or maintaining allele-specific DNA methylation at ICRs.30–32
Similar RNA interference–based YY1 knockdown experiments produced global changes in
the expression levels of multiple imprinted genes within an imprinted domain, also
confirming YY1’s role as a trans factor controlling the transcription of imprinted genes.30,31
Genome-wide surveys indicate that a small number of genomic loci (fewer than 10) contain
clusters of YY1 binding sites similar to those in ICRs and the YY1 locus itself.13 The reason
these loci need to maintain clusters of YY1 binding sites currently is unknown. Given all the
known information about YY1 and genomic imprinting, we predict that the following
scenarios most likely influence this cluster maintenance: (1) Clustered YY1 binding sites
may be designed for securing a sufficient amount of YY1 protein, locally, around ICRs for
their functional needs, such as DNA methylation during gametogenesis or transcriptional
control in somatic cells. YY1’s involvement in many diverse cellular pathways places a high
demand on its total protein levels; thus, securing sufficient amounts of YY1 protein likely is
critical for the functional needs of imprinted genes. (2) Clustered YY1 binding sites inside
ICRs also could function as individual molecular rheostats, similar to the binding clusters in
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the YY1 locus itself (Fig. 2B). It has been well-established that genomic imprinting is
essentially a gene dosage control mechanism; thus, even slight changes in the expressed
amount of imprinted genes are not tolerable for the survival of cells or organisms.14,15
Imprinted genes might use clusters of YY1 binding sites to control their transcription rates
in response to fluctuating cellular conditions. In this case, subtle changes in cellular YY1
protein levels may function to modulate temporarily the transcriptional activity of imprinted
genes. These possibilities remain to be investigated, but we strongly believe that one or both
of these scenarios may be responsible for the presence of clusters of YY1 binding sites for
these loci. In summary, the clusters of YY1 binding sites found within ICRs are unique, and
we predict that the cellular levels of YY1 protein play a critical role in regulating the
transcriptional rate of imprinted genes, possibly through the clusters of YY1 binding sites.
IV. ONCOGENIC POTENTIAL OF YIN YANG 1 THROUGH IMPRINTED
GENES
Literature reviews have established that gene expression of YY1 generally is higher in many
tumor tissues compared with their normal counterparts.7,11,33 Increased YY1 expression can
correlate with either positive or negative disease outcomes, based on both a given cancer
type and the treatment regime employed. This disparity may result from increased YY1
expression inducing cell growth in some tumors while at the same time making other tumors
more susceptible to established chemotherapeutics (such as treatment with taxanes).11 This
variability also may arise partially from YY1’s ability to interact with multiple transcription
factors to facilitate gene activation, repression, or suppression in different cellular contexts.
Newly developed cancer treatment regimens have employed either trichostatin A (a histone
deacetylase inhibitor) or 5-azacitidine (a DNA methyltransferase inhibitor) and have
demonstrated a reversal in cancer growth or progression.34–38 Some of these studies also
have tied this drug-induced reversal in cancer progression to changes in either YY1’s protein
complex recruitment abilities or its DNA binding properties. Thus, it is possible that a main
function of YY1 in cancer is to modulate epigenetic marks at specific gene loci, ultimately
to control gene expression. Although YY1 can regulate a diverse set of genes, its modulation
of multiple imprinted gene loci may prove to have some of the more profound effects on its
correlation to cancer outcomes.7
Originally, genomic studies from tumors of single-parent origin demonstrated that an
imbalance of imprinted genes, through changes in gene dosage, could result in tumor
formation.39 More recent molecular studies have illustrated that changes at imprinted loci
may be responsible for embryonic rhabdomyosarcoma and other childhood tumors.40,41
Imprinted genes, being expressed from only one allele, are exceedingly vulnerable to
epigenetic and expression changes; thus, they are often altered in multiple cancer types.
Although these alterations have been reported modestly in the scientific literature (Table 1),
their mechanism of change has not been well established. Given that YY1 recently was
shown to regulate directly 4 imprinted genes—PEG3, GNAS, small nuclear
ribonucleoprotein N (SNRPN), and XIST—that also are altered greatly in cancer, it is
possible that changes in this regulation are a mechanism for cancer growth and/or
progression.
Loss of PEG3 expression, well-documented in ovarian carcinoma and glioblastoma, was
shown to be significantly correlated with increased DNA methylation of the paternal allele
(from which PEG3 is expressed) and not genomic mutation.42–47 This aberrant DNA
methylation also was reversible by treatment with 5-azactidine. Down-regulation of PEG3
correlated significantly with advanced tumor stage in glioblastoma and increased tumor
growth in ovarian cancer. Both overexpression of PEG3 and knockdown of YY1 have been
independently shown to inhibit growth in ovarian cancer cell lines. Although YY1
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expression has not been analyzed thoroughly in glioblastoma, its overexpression in ovarian
cancer is well documented.11 Recent studies have established that YY1 interacts with only
the unmethylated allele of PEG3 to repress directly its gene expression.13 This mechanism
seems to be compromised in ovarian cancer, where PEG3 has become repressed irreversibly
and YY1 consistently overexpressed. This fact also may be true for glioblastoma, breast, and
colon cancers as well, though further research is needed to draw these conclusions.
Like PEG3, the imprinted gene SNRPN commonly is down-regulated in cancer through
either increased DNA methylation or genomic deletion.48–54 Notably, only deletion of the
paternal allele, from which SNRPN is expressed, is known to cause disease. Thus, down-
regulation of SNRPN correlates with enhanced germ cell tumor development and an
increased risk of myeloid leukemia. Unlike PEG3, YY1 was demonstrated to increase
SNRPN expression through binding of the unmethylated paternal allele.30,55 YY1
expression was demonstrated to increase in various testicular germ cell tumors and in
myeloid leukemia, though the significance of this remains elusive.11,33 Ultimately, the initial
increased methylation of the PEG3 and SNRPN genes in cancer could be caused by changes
in YY1 protein levels. If consistent YY1 protein levels are responsible for protecting and
maintaining the somatic DNA methylation status of these genes, changes in the intracellular
conditions of cancer cells may alter YY1’s ability to perform this function.
Another genomic location associated with YY1 binding, GNAS, demonstrates a more
complex imprinting mechanism involving multiple, overlapping, imprinted gene transcripts.
In contrast to both the PEG3 and SNRPN loci, the GNAS locus generally is expressed at
higher-than-normal levels in many tumor types.56–59 GNAS overexpression was
demonstrated to correlate with a worsening cancer phenotype for diseases such as ovarian
cancer, melanoma, and intraductal papillary mucinous neoplasms. Although the main
changes to GNAS expression in cancer tend to be mutation of the active allele, changes in its
imprinting status or genomic amplification also have been observed. Given the complexity
of the GNAS locus with respect to changes in YY1 binding, some transcripts become down-
regulated whereas others are induced, and YY1 may function as a pure transcriptional
activator/repressor of this genomic region.30,31 Thus, changes in YY1 protein levels in the
cellular environment of cancer may be responsible for the alterations in expression at the
GNAS locus through binding of the clustered YY1 sites in this locus. This type of
mechanism also may be true for regulation of the XIST gene. XIST alterations in cancer
tend to stem from either loss of the inactive X chromosome or gain of expression from the
active X chromosome. 60–63 Reduced YY1 levels were documented to cause loss of DNA
methylation at the XIST allele, suggesting that altering YY1 levels may cause increased
expression of XIST.32 Conversely, YY1’s recently characterized ability to bind both XIST
RNA and DNA during the process of X chromosome inactivation ultimately may be
compromised in the cancer environment.64 Thus, for imprinted genes that gain function in
cancer cells, YY1’s role in this change may originate from its ability to function as a
transcription factor that has both repression and activation capabilities.
V. CONCLUSIONS
Given YY1’s ubiquitous expression in multiple cell types, it has the potential to influence
cancer progression in a variety of ways. Asserting its ability through modulation of
imprinted genes seems likely, given that these genes are highly susceptible to changes in the
cellular environment. Though the exact mechanism by which YY1 regulates imprinted
genes is still poorly defined, understanding this mode of regulation may assist with defining
YY1 as either an oncogene or tumor suppressor; it is quite possible that YY1 can be either,
depending on the exact subset of genes it modulates within a specific tumor type. Moreover,
the amount of YY1 in the cellular environment seems to be an increasingly important factor
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with respect to YY1 function at clusters of YY1 binding sites. Given that the dosage of
imprinted genes, many of which contain YY1 binding clusters, must be strictly maintained
for cellular survival (and possibly genomic stability), fluctuations in YY1 protein levels may
create or perpetuate a cancerous cellular environment through alterations in the
transcriptional regulation of imprinted genes. Overall, uncontrolled alterations in YY1
protein levels may result in tumor growth and/or development.
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Evolutionary conservation of Yin Yang (YY) 1. A, Schematic representation of the YY1
proteins of mammals (top) and flying insects (bottom) demonstrating the strict conservation
of the entire protein. The YY1 proteins of mammals (414 amino acids long) and flies (520
amino acids long) are divided into 5 and 6 regions, respectively, based on their exon
structures. B, Sequence comparison of the zinc-finger domains of YY1 from different
species illustrating the limited amino acid changes in the YY1 zinc-finger domains.
Conservative and nonconservative amino acid substitutions are indicated by green and red,
respectively.
Thiaville and Kim Page 10














The cluster of Yin Yang (YY) 1 binding sites in the YY1 locus and its potential role for the
homeostasis of YY1 protein. A, Evolutionary conservation of the cluster of YY1 binding
sites within the first intron of vertebrate YY1. DNA sequences for the 80-basepair genomic
regions containing the clusters of YY1 binding sites are aligned. The YY1 binding sites in
the forward direction are marked in blue, whereas the YY1 binding sites in the reverse
direction are in green. B, The genomic structure of mouse YY1 is presented with closed
boxes as exons. The YY1 binding sites within the first intron are indicated with circles (top).
A schematic representation of the functional mode of the cluster of YY1 binding sites is
shown below. At normal levels of YY1 protein (indicated by arrows), the YY1 protein
occupies half of the YY1 binding sites with the normal transcription rate of YY1. However,
the transcription rate of the YY1 locus can be either up- or down-regulated at lower or
higher levels of the available YY1 protein, respectively. This switch between activator and
repressor roles may be feasible by the different levels of occupancy on the cluster of YY1
binding sites by the YY1 protein (bottom panel).
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TABLE 1








PEG3 (paternal expression) Down/ovarian, cervical, endometrial
cancers
Increased DNA methylation Increased tumor growth and
progression
42–44
Down/glioblastoma Increased DNA methylation Grade 4 tumors 45–47
Up/choriocarcinomas Loss of maternal imprinting ? 42
Down/breast, colon Increased DNA methylation Increased cell line growth
(casual)
48
SNRPN (paternal expression) Down/breast, colon Increased DNA methylation ? 48
Slightly up/uterian tumor ? ? 49






Genomic deletion Older patient age at disease
onset
52
Down/AML Increased DNA methylation No obvious correlation to
cancer
53
Down/PWS Genomic deletion Increased myeloid leukemia
risk
54
GNAS (maternal expression) Up/ovarian cancer Genomic amplification Poor progression-free survival 56
Up/pituitary adenomas Activating mutation and
loss of imprinting














Up/breast cancer Misregulation of messenger
RNA
? 60
Down/ovarian cancer Loss of inactive X
chromsome
Shorter disease-free period 61,62
Up/breast and cervical cancer Gain expression from
active X chromosome
? 61,63
AML, Acute Myeloid Leukemia; GNAS, guanine nucleotide binding protein alpha stimulating; PEG3, paternally expressed gene 3; PWS, Prader-
Willi Syndrome; SNP, Single Nucleotide Polymorphism; SNRPN, small nuclear ribonucleoprotein; XIST, X (inactive) specific transcript.
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